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Despite advances in systemic therapies for solid tumors, the development of brain
metastases remains a significant contributor to overall cancer mortality and requires
improved methods for diagnosing and treating these lesions. Similarly, the prognosis for
malignant primary brain tumors remains poor with little improvement in overall survival
over the last several decades. In both primary and metastatic central nervous system
(CNS) tumors, the challenge from a clinical perspective centers on detecting CNS
dissemination early and understanding how CNS lesions differ from the primary tumor,
in order to determine potential treatment strategies. Acquiring tissue from CNS tumors
has historically been accomplished through invasive neurosurgical procedures, which
restricts the number of patients to those who can safely undergo a surgical procedure,
and for which such interventions will add meaningful value to the care of the patient.
In this review we discuss the potential of analyzing cell free DNA shed from tumor cells
that is contained within the cerebrospinal fluid (CSF) as a sensitive and minimally invasive
method to detect and characterize primary and metastatic tumors in the CNS.
Keywords: brain tumor, CSF (cerebrospinal fluid), genomic profiling, metastatic disease, circulating tumor
DNA (ctDNA)
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INTRODUCTION

primary brain tumor patients is limited, with only a minority
yielding detectable levels. Across published reports, the rate of
ctDNA detection in plasma for primary brain tumors varies from
10 to 50% of samples with higher detection rates associated
with glioblastoma; however, all studies consistently report that
even when detected, the ctDNA concentrations are much lower
compared to other advanced stage tumors (3, 5–7). Although
investigations are ongoing to determine why over half of
high-grade glioma patients do not have detectable ctDNA in
plasma, one likely contributor is the blood brain barrier (BBB)
preventing both intact tumor cells and tumor cell-free DNA
from reaching the peripheral circulation system. Recently one
study demonstrated that the levels of plasma ctDNA from GBM
patients were associated with increased BBB permeability, the
density of macrophages around the tumor and the size of
tumor vessels, supporting the hypothesis that the BBB integrity
significantly influences ctDNA levels in the plasma of primary
brain tumor patients (8).
Several studies have identified cerebrospinal fluid (CSF) as a
rich and reliable source of ctDNA (ctDNA-CSF) in patients with
primary and metastatic brain tumors. Secreted by the choroid
plexus, CSF is a clear body fluid in the subarachnoid space of
the brain and spinal cord that provides specialized immunologic
protections and serves as a cushion for the brain (9). Given its
direct contact with brain and relative ease of access through
lumbar puncture, CSF could have major advantages over plasma
for evaluating ctDNA for patients with metastatic and primary
brain tumors.
In this review we will explore CSF testing for primary and
metastatic brain tumors and discuss the clinical utility of testing
for management of patients affected by brain cancer.

Comprehensive genomic profiling (CGP) of formalin-fixed
paraffin-embedded (FFPE) tumor tissues has allowed many
cancer patients to benefit from precision medicine by
identifying genomic alterations for which targeted therapy
or immunotherapy may be preferentially utilized. While the
clinical value of tissue based CGP is well-established, this
approach requires patients to undergo a tissue acquisition
procedure such as a fine need aspiration, core biopsy, or surgical
resection. As nearly all patients will be biopsied at presentation
to establish a tissue diagnosis of malignancy, there is often tumor
tissue available for CGP.
Despite advancements in therapeutic strategies for solid
tumors, progression frequently occurs, manifesting as metastatic
disease or recurrence. At this point, the ability to acquire a
second biopsy can be challenging for several reasons including,
the patient’s general health status, the ability and/or willingness
to undergo another invasive procedure, and the patient’s safety
associated with the location of the lesion to be biopsied. For
patients with primary brain tumors (e.g., glioblastoma), most
patients will undergo a tissue sampling procedure at the time
of presentation to establish the diagnosis, while only a subset
(10–20%) of patients will ever have a second procedure to
acquire tissue at tumor recurrence (1, 2). Thus, 80% of primary
brain tumor patients have no access to updated genomic data
at the time of their post-initial treatment tumor progression
highlighting a critical unmet need for this patient population.
As such, in many instances when cancer patients are in critical
need of new information to help guide their clinical management,
tissue-based CGP may not be feasible.
To overcome this clinical challenge, recent advances in
isolating circulating tumor DNA (ctDNA) from the plasma of
peripheral blood samples has provided a novel mechanism for
interrogating the genomic landscape of tumors without invasive
surgical procedures. This type of assay is frequently referred to as
a “liquid biopsy” and encompasses a broad category of minimally
invasive tests that can effectively isolate DNA shed from cancer
cells that are circulating in the blood or other relevant fluids.
In contrast to circulating tumor cells (CTCs), which are intact
tumor cells in the peripheral circulation, ctDNA is a component
of the total circulating “cell-free” or cfDNA that includes both
ctDNA and DNA fragments in plasma contributed by white
blood cells and apoptotic normal non-hematologic cells. ctDNA
testing platforms range from variant-specific and “hot-spot”
assays to broad next generation sequencing panels that can assess
for variants in hundreds of genes simultaneously. For some solid
tumors, such as breast, lung, prostate, melanoma and colorectal
cancers, ctDNA assays have demonstrated strong concordance
of genomic profiles compared to tissue-based assays (3, 4).
Moreover, ctDNA analysis for these patients before and after
treatment have shown significant correlations between ctDNA
levels and tumor response to treatment, highlighting further
potential clinical utility for this platform both as stand-alone
prognostic tests and potential monitoring assays.
While advanced-stage tumors demonstrate increasing yields
of ctDNA in the plasma, detecting ctDNA in the plasma of
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Improved Yields From ctDNA-CSF
Compared to Pelleted Cells From CSF
For tumors that arise outside of the CNS (e.g., lung cancer),
the presence of tumor cells in the CSF correlates with poor
response to therapy and overall poor prognosis (10, 11). To
determine the spread of cancer to the brain or spinal cord,
current methodologies rely on neuro-imaging, clinical findings
such mental status changes, new onset headaches, presence
of cauda equina syndrome, changes in sensory status and
microscopic evaluation (cytology) or flow cytometry of CSF.
For some cancers, particularly acute lymphoblastic leukemias,
effective, early detection of infiltrating tumors cells in the CSF
maximizes the ability to provide early and effective therapeutic
intervention (12).
CSF is typically collected through a minimally invasive lumbar
puncture but can also be accessed via existing shunts or during
intracranial surgical procedures, with a typical volume of 2–10
mLs of fluid with each collection. Current methodologies for
evaluating CSF focus on determining the presence of cancer
cells with cytology, immunohistochemistry, or flow cytometry;
however, while these techniques can be highly specific, they lack
the sensitivity that is needed for early detection of malignancy.
As an alternative, ctDNA from the CSF (ctDNA-CSF) can
be extracted and sequenced, which increases sensitivity and
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FIGURE 1 | Generalized workflow for collection, processing, and analysis of cell-free ctDNA and intact cells from cerebrospinal fluid.

provides additional information about tumor heterogeneity and
progression of disease [(13); Figures 1, 2]. In the CSF, there are
two sources of tumor DNA: intact cells and cell-free ctDNA,
which is shed from tumor cells and circulates within the CSF.
To collect the ctDNA-CSF, CSF samples are centrifuged within
hours of collection and the supernatant carefully removed, while
the remaining pellet can be re-suspended and used for additional
analyses. Both the supernatant and cell pellet can either be
frozen for later testing or the DNA can be immediately extracted.
Specific kits for DNA extraction of circulating nucleic acids
are available and typically protocols from the manufacturers
are followed (14–16). The extracted DNA from both ctDNACSF in the supernatant and tumor cell DNA contained in
the pelleted populations can then be evaluated for tumorspecific alterations, such as recurrent mutations, with more
focused digital droplet PCR, or be evaluated with next-generation
sequencing using a large gene panel, whole exome or genome
platforms (Figures 1, 2).
Because normal white blood cells can be found within the CSF
of both normal and cancer patients, several studies have been
performed to compare enrichment of tumor specific variants in
DNA from the CSF supernatant compared to DNA from pelleted
cells within the CSF. Even though they are typically present in
low numbers, the DNA obtained from white blood cells can
potentially mask low-level tumor specific variants; therefore,
determining which population provides more reliable, tumorspecific information is critical for achieving the greatest clinical
utility. Pentsova et al. demonstrated in cancer patients with
established brain metastases from solid tumors that although
DNA yields were generally higher in the CSF pelleted population,
a higher percentage of sequence reads with a known mutation
was present in the ctDNA-CSF supernatant compared with the
CSF pellet DNA (17). This trend was similar for copy number
alterations as well, which was illustrated by a metastatic breast
cancer sample that demonstrated significant HER2 amplification
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FIGURE 2 | Comparison of digital droplet PCR (ddPCR) and next generation
sequencing platforms in the analysis of ctDNA-CSF.

in the ctDNA-CSF sample but barely detectable levels in the
pelleted fraction. In all, known variants were detected in 100%
of ctDNA-CSF samples but only 63% of CSF cell pellets from
their cohort (17). Similarly, in a cohort of EGFR-mutated NSCLC
patients, the EGFR mutation was detected in 100% (26/26) of
ctDNA-CSF samples, however only 84.6% (22/26) and 73.1%
(19/26) of pelleted CSF and plasma ctDNA samples, respectively,
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TABLE 1 | Summary of studies demonstrating clinical utility of ctDNA-CSF in CNS disease.
Study

Tumor types

Number of samples

Assay method

Analyte

Mutation detection
rate

De Mattos-Arruda et al. PMID:
26554728

Breast, lung, GBM

n = 12

Targeted sequencing

CSF

60%

Plasma

55%

Pentsova et al. PMID: 27161972

Advanced solid tumors
and primary CNS
tumors

n = 32

Targeted sequencing

CSF

60–75%

Li et al. PMID: 29346604

NSCLC

n = 26

Targeted sequencing

CSF

100%

Plasma

73%

Bettegowda et al. PMID:
24553385

Advanced solid tumors
and primary CNS
tumors

n = 640

Targeted sequencing

Plasma

>75% for most solid
tumors

Zill et al. PMID: 29776953

Advanced solid tumors
and primary CNS
tumors

n = 21,807

Targeted sequencing

Plasma

51–93%

Wang et al. PMID: 26195750

Primary CNS tumors

n = 35

Targeted sequencing

CSF

74%

Miller et al. PMID: 30675060

Primary CNS tumors

n = 85

Targeted sequencing

CSF

50%

Plasma

0%

von Baumgarten et al. PMID:
31903155

Advanced solid tumors

n=27

Targeted sequencing

CSF

74%

Martinez-Ricarte et al. PMID:
29615461

Primary CNS tumors

n = 20

Targeted sequencing

CSF

79%

Momtaz et al. PMID: 27863426

Advanced melanoma

n = 11

Digital droplet PCR
(ddPCR)

CSF

55%

Schwaederle et al. PMID:
26848768

Advanced solid tumors
and GBM

n = 171

Targeted Sequencing

Plasma

65%

Piccioni et al. PMID: 30855176

Primary CNS tumors

n = 419

Targeted sequencing

Plasma

50%

Mouliere et al. PMID: 30401727

Primary CNS tumors

n = 13

Shallow whole genome
sequencing

CSF

39%

Pan et al. PMID: 25605683

Advanced solid tumors
and primary CNS
tumors

n=7

ddPCR

Targeted sequencing

Plasma

Bobillo et al. PMID: 32079701

B-cell lymphoma

n = 19

ddPCR

CSF

Targeted sequencing

Plasma

ddPCR

CSF

Plasma

Huang et al. PMID: 31161597

Lung adenocarcinoma

n = 35

CSF

86%

32%
50–75%

Plasma

metastases that had negative cytology and radiologic findings for
leptomeningeal disease (20). These studies and others highlight
the increased sensitivity of ctDNA-CSF testing compared to
traditional cytology studies (Table 1).

identified the mutation (4). The ctDNA-CSF allele fractions were
also significantly higher compared to other sample types.
Importantly, multiple studies evaluating ctDNA-CSF in
primary CNS tumors and brain metastases report high
concordance between genomic profiles detected in tissue samples
compared to those from ctDNA-CSF analyses (4, 17–19).
Furthermore, there is strong evidence that ctDNA-CSF correlates
with positive cytology results, wherein increasing levels of
ctDNA-CSF are noted when cytology results are also positive
for tumor cells. However, in patients with negative cytology
findings but radiologic evidence for CNS metastases, ctDNACSF detected high-confidence somatic alterations in an average
of 25% of patients (17). Another study reported that ctDNACSF detected mutations in 62% (5/8) patients with brain
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Clinical Utility of ctDNA-CSF Testing in
CNS Metastases
The development of metastatic disease involving the CNS is
associated with a poor prognosis, therefore, a first step to
improving outcomes for these patients is understanding the
genomic landscape of brain metastases which most often go
unsampled. Testing of ctDNA-CSF may also help confirm CNS
involvement in instances where the results of neuro-imaging
studies are equivocal. Current methodologies to detect tumor
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metastases or neoplastic meningitis rely on radiologic changes,
correlation of pertinent clinical symptoms and/or the presence of
tumor cells in the CSF by cytology; however, these methods lack
the sensitivity required to identify disease early, necessitating the
need for more sensitive, minimally invasive approaches.
For non-CNS solid tumors there is growing evidence that
monitoring ctDNA from plasma provides information about
systemic disease response to treatment and emergence of targeted
therapy-associated resistance mutations. Because of the strong
concordance of mutational profiles between tissue and ctDNA,
monitoring the levels and mutational status of ctDNA in breast,
colorectal and non-small cell lung cancers have demonstrated
significant clinical utility. Indeed, in breast cancer patients
increasing ctDNA levels are associated with inferior survival and
increased risk of recurrence, while one study reported 96% of
EGFR-mutated colorectal or NSCLCs demonstrated a reduction
in ctDNA plasma levels after initiation of targeted therapy (21).
It has been shown that in more than 50% of cases, solid tumor
metastases to the brain harbor clinically relevant mutations
that were not detected in the primary tumor (22). Monitoring
mutational profiles of tumors with a high rate of metastasis over
the course of a patient’s treatment plan can provide meaningful
information that may guide clinical management. Importantly
for brain metastases, several studies have demonstrated that
analyzing ctDNA-CSF offers a more sensitive and specific
source of tumor-specific mutations compared to plasma ctDNA
(4, 19, 23). In one study from a cohort of 53 patients
with molecular profiling of ctDNA-CSF, 12 patients developed
CNS tumor progression while on a targeted kinase inhibitor
therapy. Of these patients, ctDNA-CSF analysis detected a
drug-resistance mutation in 33% of patients. Importantly these
mutations were not identified in the primary tumor tissue (17).
Similarly, in a cohort of 26 EGFR-mutated NSCLC patients
with leptomeningeal metastases, unique genomic profiles were
detected from ctDNA-CSF compared to the primary tumor or
plasma ctDNA, including increased MET copy number gains and
TP53 loss of heterozygosity (4). Additionally, it has been shown
that ctDNA-CSF harbors private mutations that are restricted
to the metastatic brain lesions and could not be identified in
other metastatic sites present in the patient. In one Li-Fraumeni
patient with both HER2-positive metastatic breast cancer and
esthesioneuroblastoma, the authors demonstrated that ctDNACSF mutation profiles were specific to the brain metastasis, while
plasma ctDNA testing reported mutations found only in the
extracranial esthesioneuroblastoma (19).
Of great clinical significance, EGFR resistance mutations
can often be detected in plasma from NSCLC patients
prior to any clinical signs of progression, suggesting that
monitoring ctDNA levels and mutational profiles over the
disease course could provide opportunities for earlier therapeutic
intervention. The EGFR resistance mutation T790M was also
detected more frequently in ctDNA-CSF (30%) compared
to plasma ctDNA (21%). In another study of patients with
leptomeningeal carcinomatosis, ctDNA-CSF analysis detected
the presence of disease in 100% of cases while neuroimaging
and CSF cytology identified 63 and 71% of cases, respectively.
In another institution’s experience, ctDNA-CSF genomic
profiling from patients with malignant CNS disease detected
Frontiers in Neurology | www.frontiersin.org

clinically actionable mutations in 40% (11/27) of patients. After
consultation with an interdisciplinary molecular tumor board,
seven patients were recommended to receive a targeted therapy
based on the ctDNA-CSF results, with four patients being
clinically stable to proceed with the new treatment regimen.
These patients included two metastatic NSCLC patients with
EGFR mutations who received erlotinib or afatinib, a NSCLC
patient with an EZR/ROS1 fusion who was treated with crizotinib
and a HER2 positive metastatic breast cancer patient with FGFR
amplification who received everolimus (20). This study
highlights the potential clinical applications for ctDNA-CSF
testing in CNS disease, wherein identifying targetable alterations
in brain metastases may offer new therapeutic opportunities.

Clinical Utility of ctDNA-CSF Genomic
Profiling in Gliomas
While ctDNA from plasma provides a reliable, representative
source for establishing and monitoring mutational profiles for
extra-cranial solid tumors, it does not offer the same sensitivity
for primary brain tumors. Bettegowda et al. demonstrated that
ctDNA from plasma is detectable in the vast majority of patients
with advanced cancers such as pancreatic, ovarian, colorectal,
breast, melanoma, and hepatocellular tumors, but <10% of
glioma patients had measurable levels of ctDNA (3). In their
study of 136 metastatic tumors, ctDNA was detected in 82%
(112/136) of cases, however the levels the ctDNA differed
significantly between tumor types. For primary brain tumors, half
of the medulloblastoma cases had detectable ctDNA in plasma
(7/14), while only two glioma patients showed detectable levels
(2/27). Similarly, another study of 33 GBMs showed that 73% of
tumors did not have any detectable ctDNA in plasma (7). In a
separate report, de Mattos et al. demonstrated that glioma specific
mutations were not detected in plasma from any of the patients
tested, which likely reflects the restrictive nature of the BBB to
prevent glioma cells and ctDNA from leaving the CNS. In this
study the sensitivity of ctDNA from plasma was compared to
CSF and in all four primary glioma samples, ctDNA-CSF detected
mutations that were identified in the primary tissue, while these
variants were not detected in plasma ctDNA.
Liquid biopsies of the CSF have been explored as a less
invasive method for obtaining molecular information specific to
the tumor that can aid in the diagnosis, prognosis, and treatment
for brain tumor patients. Several studies have demonstrated that
ctDNA from primary brain tumors is enriched in CSF, with
detection rates similar to those reported for other advanced
cancers using ctDNA from plasma (17, 19, 24). The ability to
detect ctDNA in the CSF does not appear to correlate with patient
demographics, presence of hydrocephalus, contrast enhancement
or tumor size; however, the levels of ctDNA-CSF in one study
correlated with tumor grade, with higher levels of ctDNA found
in high-grade tumors compared to low-grade lesions (25). This
correlation, however, did not hold true for adult gliomas as a
larger study that analyzed 85 WHO grade II-IV adult gliomas
did not find an association between ctDNA-CSF positivity and
tumor grade (24). The strongest factor influencing ctDNA-CSF
levels, however, is anatomic location. When tumors are adjacent
to CSF spaces, such as cortical surfaces and ventricles, a higher
percentage of tumors have detectable ctDNA levels compared to
5
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the CNS is the second most common location for extragonadal
tumors. These are a heterogeneous group of tumors that can
be difficult to diagnose because of their non-specific clinical
presentations and subsequently predict which tumors are more
likely to metastasize to the brain. The propensity to spread
throughout the CNS increases the need for highly specific and
sensitive markers that can be detected in the CSF of patients.
Currently monitoring certain protein biomarkers such as alphafetoprotein and human chorionic gonadotropin within the CSF
only provides information for certain GCT subtypes and has
limited sensitivity in terms of diagnosing CNS dissemination
(28). There is however increased interest in evaluating the utility
of molecular biomarkers present in the CSF of GCT patients. One
study has demonstrated the feasibility to detect microRNAs in
CSF that have been reported to be overexpressed in malignant
germ cell tissues (29).
Primary CNS lymphoma (PCNSL) patients may also benefit
from CSF liquid biopsies as these tumors often disseminate
via CSF. Notably, surgical resection is not standard of care,
and if PCNSL is diagnosed during an intraoperative frozen
section, the surgical procedure is routinely stopped as this disease
is best managed with chemotherapy. While this is considered
best practice, it does limit the amount of tissue available for
genomic testing and further reduces the likelihood of additional
tissue sampling at the time of tumor recurrence. Detection of
mutational profiles and immunoglobulin gene rearrangements
in CSF has the potential to improve diagnostic sensitivity,
especially in setting of steroid administration, which can make
tissue sampling of PCNSL challenging because of tumor cell
lysis. In contrast, one can speculate that the use of steroids
for PCNSL prior to ctDNA-CSF liquid biopsy may enhance
the amount of ctDNA available in the CSF compartment. In
one study 19 patients with B-cell lymphomas were evaluated to
compare the utility of ctDNA-CSF or plasma in diagnosing CNS
involvement and explore whether the analysis of ctDNA could
monitor treatment response in CNS lymphomas (30). Genomic
analysis of ctDNA from either CSF or plasma demonstrated
readily detectable ctDNA-CSF in all 6 cases of CNS restricted
lymphomas, while plasma ctDNA was only detected in 2
out of 6 cases, highlighting the sensitivity of ctDNA-CSF
compared to plasma. This analysis also showed that tumor
burden, measured by MRI or flow cytometry, was concordant
with ctDNA-CSF levels but not plasma ctDNA. Moreover,
ctDNA-CSF demonstrated an increased sensitivity for detecting
CNS involvement compared to conventional cytology or flow
cytometry (30).
Further utility for CSF liquid biopsy in PCNSL includes
identifying tumor recurrence, particularly in cases associated
with extensive leptomeningeal involvement in which diagnosing
recurrent tumor in the post-treatment setting solely by neuroimaging studies can be very difficult, often when cytologic
analysis is unrevealing. Indeed, sequential ctDNA-CSF testing
in patients undergoing treatment demonstrated that despite a
decrease in tumor cells by flow cytometry or in some cases
no detectable disease by conventional techniques, patients still
harbored CNS disease when assessed with a more sensitive
method (30).

tumors that are encapsulated (24, 25). In a study of 20 diffuse
gliomas, only three cases were identified wherein mutational
profiles from ctDNA-CSF did not match the mutations detected
in tissue, while the other 17 samples had corresponding genomic
profiles in the CSF and the primary tumor. It was hypothesized
that the distance from the cortex or ventricles contributed to the
discordance (26).
The molecular characterization of the ctDNA-CSF in patients
with primary brain tumors has demonstrated the ability to
capture a broad spectrum of mutations and copy number
alterations that resemble the mutational profiles of tumor
biopsies. In adult gliomas, comparison of the tumor mutation
burden and frequency of mutations was comparable between
ctDNA-CSF and tissue genomic analyses. The most commonly
detected alterations in ctDNA-CSF were truncal variants
including TERT promoter, TP53 and IDH1 mutations as well as
CDKN2A/B deletions. Clonal mutations are more likely to also
be detected in ctDNA-CSF, however, subclonal mutations were
more likely to be identified in tissue (24, 27).
Longitudinal studies have also highlighted the ability of
ctDNA-CSF to capture the genomic response to treatment
and tumor evolution. In one patient with a 1p/19q co-deleted
oligodendroglioma, ctDNA-CSF analysis 7.5 years after the initial
diagnosis reported >400 non-synonymous single nucleotide
variants in a pattern commonly associated with exposure to
alkylating agents such as temozolomide (17). Additionally, when
CSF samples collected at diagnosis were compared to CSF
collected at the time of recurrence (18 months) the ctDNACSF mutational profiles diverged with later samples harboring
an increase in mutations of genes associated with growth factor
signaling pathways or in genes that were mutated in the primary
sample (24). The molecular evolution observed from ctDNACSF analyses recapitulated the patterns that have been previously
reported in studies of sequential tumor biopsies, highlighting the
possibility that ctDNA-CSF could substitute for tissue testing in
some patients.
Published studies have demonstrated that detection of ctDNACSF provides prognostic implications for glioma patients. The
presence of ctDNA-CSF was associated with a four-fold higher
risk of death in adult glioma patients compared to patients
without detectable levels. To illustrate the increased sensitivity of
ctDNA-CSF, most of the patients with ctDNA-positive CSF did
not have detectable malignant cells in the CSF by cytopathologic
analysis. In a multivariate analysis, the presence of ctDNA-CSF
remained a statistically significant prognostic factor (24).

Clinical Utility in Non-glial Primary CNS
Tumors
The utility of molecular profiling of ctDNA-CSF is not limited
to primary glial tumors as other CNS tumors face similar
diagnostic and clinical management challenges. Exploring the
sensitivity and specificity of ctDNA-CSF in non-glial CNS tumors
may provide alternative methods that can aid in diagnosis or
identification of disease recurrence.
Although primary germ cell tumors (GCTs) only represent 1%
of primary brain tumors in pediatric and young adult patients,
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There is significant potential for ctDNA-CSF testing to disrupt
the way neuro-oncology is currently practiced by providing
neurosurgeons, oncologists and patients with pre-surgical, preradiation and pre-systemic therapy genomic diagnoses that
can inform clinical management strategies. The value of total
and near-total resection for high grade gliomas remains an
important therapeutic and prognostic indicator. ctDNA-CSF
molecular analysis has the potential to provide more information
to neurosurgeons for planning surgical procedures based on
genomic profiles. In instances where the tumor is based in an
eloquent area of the brain or deep gray structures where resection
is not possible and the purpose of surgical intervention is solely
to sample tissue for diagnosis, CSF ctDNA testing may be an
alternative to biopsy procedures.
As several studies have demonstrated, ctDNA-CSF sequencing
can also provide opportunities for early detection of metastatic
disease, which may have significant implications for therapeutic
intervention. Retrospective studies have demonstrated that in the
context of metastatic disease ctDNA-CSF mutations reflect CNS
specific alterations, which are not identified in plasma ctDNA or
extracranial metastases (19). Incorporating ctDNA-CSF genomic
analysis along with traditional cytology, radiologic and other
methodologies will refine the utility and sensitivity of detecting
CNS disease. Early detection of novel activating mutations in
ctDNA-CSF provides the opportunity to investigate utility of
targeted therapies, while detection of resistance mutations offers
the ability to treat with combination therapies that target multiple
primary therapy resistant clones. Furthermore, monitoring levels
of ctDNA-CSF can offer insights into the efficacy of therapeutic
strategies and potentially guide dosing and treatment duration.
For HER2 positive breast cancer patients, treatment with
monoclonal antibodies or tyrosine kinase inhibitors demonstrate
significant efficacy for systemic disease, however these therapies
also increase the prevalence of CNS metastases as the brain may
protect tumor cells from the effects of these treatments (38, 39).
ctDNA-CSF has shown significant utility in providing biomarkers
to demonstrate response to treatment for CNS disease. One study
demonstrated that in contrast to plasma ctDNA which showed
decreasing ERBB2 levels and other tumor-specific mutations
during treatment with trastuzumab emtansine, CSF ctDNA
revealed continued high levels of ERBB2, MYC copy numbers,
PIK3CA, and TP53 mutations, which were identified prior to the
start of treatment (40). This highlights the ability of ctDNA-CSF
monitoring to inform how metastatic CNS disease is responding
to treatment. In one study monitoring H3F3A K27M levels in
CSF ctDNA correlated with the presence of contrast-enhancing
areas on MRI in pediatric DIPGs (41).
Importantly, to fully understand the potential of ctDNACSF testing and incorporate the methodology into routine
clinical care, prospective clinical trials are needed. Larger studies
should be performed that evaluate the correlations between
ctDNA-CSF, plasma ctDNA and tumor tissue samples. Future
prospective studies that incorporate ctDNA-CSF testing in
parallel with standard of care diagnostic and management
procedures will help refine and implement the utility of
ctDNA-CSF testing for patients with brain metastases and
primary tumors.

With recent data highlighting clinical utility of the Bruton
tyrosine kinase inhibitor (BTKi) ibrutinib as monotherapy in
salvage treatment of PCNSL, this highlights the value of mapping
the genomic landscape of recurrent PCNSL. While BTKi may
become an important option for salvage therapy, it is worth
noting that several mechanisms of resistance have been identified
including mutations in MYD88, CARD11, TNFAIP3, and CD79B.
Therefore, in the recurrent PCNSL setting, should CSF liquid
biopsy identify mutations in these key genes, it would likely guide
therapy away from BTKi (31–33).

Clinical Decision Making for Brain Tumor
Patients Based on ctDNA-CSF Testing
Liquid biopsies are increasingly demonstrating clinical utility for
a variety of cancers. Guidelines have evolved most rapidly in nonCNS cancers such as lung cancer where CAP guidelines suggest
that liquid biopsy may be acceptable at the time of diagnosis
should tissue not be available for testing.
Additionally, this methodology can help clarify radiologic
findings and differentiate between radiation-induced necrosis
and tumor progression. Pseudoprogression, defined as postradiotherapy changes that typically resolve spontaneously, occurs
in 10–30% of GBM patients typically within the first 12 weeks
of treatment (34). The ability to distinguish these changes from
true disease progression is critical for patient management, as
deciding between the scenarios can mean additional treatment,
change in treatment strategy, or another invasive surgical
intervention. Currently there is a need for specific biomarkers
that can be used to discriminate between disease recurrence
and pseudoprogression. cfDNA has demonstrated utility in
discerning between these in non-CNS tumors and initial studies
are providing proof of concept evidence that the presence of
tumor specific ctDNA yield (ng) and mutations in ctDNA-CSF
after treatment are biomarkers that can be used in conjunction
with radiologic findings to guide clinical management (35–37).
Molecular assessment of ctDNA-CSF can also assist in
diagnosis and classification of tumors which, due to their
anatomic location in the CNS, cannot be biopsied for a histologic
diagnosis. For example, in patients with midline gliomas such
as diffuse intrinsic pontine glioma (DIPG), given the anatomic
location, it is often not possible to biopsy these patients and
therefore they are routinely treated clinically based on imaging
studies. If however ctDNA-CSF testing was available and showed
a H3F3A (K27M) mutation, it would suggest a molecular
diagnosis of diffuse midline glioma, H3F3A K27M mutant, WHO
Grade IV; alternatively, if the tumor harbored a KIAA1549BRAF fusion, that would suggest a lower grade glioma such as
pilocytic astrocytoma WHO Grade I. A retrospective study of
20 glioma patients demonstrated combined digital droplet PCR
and targeted sequencing of known glioma associated mutations
on ctDNA-CSF samples could correctly classify gliomas in 85%
of cases; the only samples that failed were low-grade gliomas
or tumors where ctDNA-CSF yields were low (26). Prospective
studies are needed to define the sensitivity, specificity, and
reproducibility of ctDNA-CSF for diagnosing gliomas.
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